Navigation Links
PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
Date:11/9/2009

BOSTON, Nov. 9 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide. PAREXEL is using Mortara Instrument's Surveyor Telemetry Central System to supplement its state-of-the-art ECG equipment to support biopharmaceutical companies in improving cardiac safety assessment of new compounds.

Designed to address the growing ECG requirements of early phase cardiac safety studies, Mortara's Surveyor Telemetry Central System allows PAREXEL to acquire and store continuous, diagnostic 12-lead ECG data, which is wirelessly transmitted from devices worn by clinical trial participants. The Mortara solution, which has been fully implemented and validated in PAREXEL's early phase clinical unit located in Baltimore, Maryland in the United States, provides live monitoring and automated acquisition and recording of ECGs for analysis and transmission to core labs. This solution extends the technology capabilities for ECG and QT/QTc studies conducted in PAREXEL's other early phase units worldwide, including sites located in Los Angeles, California in the United States as well as in London, United Kingdom; Berlin, Germany; and Bloemfontein, George, and Port Elizabeth, South Africa.

"With growing regulatory requirements, cardiac safety studies have become increasingly important within a clinical development program. We help biopharmaceutical companies gather cardiac safety data early in the development cycle for maximum efficiency," said Michelle Middle, MB ChB, Corporate Vice President and Worldwide Head of Early Phase, PAR
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
11. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 6 month results from long term durability study presented ... Section meeting of the American Urological Association, ... of innovative therapies in women,s health, announced today that,six ... to,evaluate the long term durability of the Renessa(R) treatment ...
... Community Oncology,Alliance (COA), representing community cancer centers ... & Medicaid Services (CMS),reconsider its decision to ... to,vital anemia-fighting drugs. Effective July 30, 2007, ... oncologists, use of,anemia-fighting drugs, referred to as ...
Cached Medicine Technology:New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 2New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence 3Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions 2
(Date:10/31/2014)... 2014 (HealthDay News) -- Carving pumpkins and trick-or-treating may ... children to emergency rooms in the United States every ... had the fifth highest number of ER visits involving ... data from the National Electronic Injury Surveillance System. ... head, noted the American Academy of Orthopaedic Surgeons and ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... all public health tactics known to prevent Ebola transmission ... epidemic, a new study reports. Four practices in ... way, immediately isolating new patients, tracing people potentially exposed ... care workers -- can stop the epidemic within six ...
(Date:10/31/2014)... National Institutes of Health will facilitate communication among ... health research, from diagnosis to treatment. The Research ... the National Institute of Mental Health (NIMH), part ... institute,s RDoC initiative. , The aim of ... of research that translates basic science into clinical ...
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
Breaking Medicine News(10 mins):Health News:Halloween at the ER Is No Treat 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3
... Mass. -- A subtle mutation affecting the epigenome - a ... lead to an inherited form of mental retardation that affects ... also involves cleft lip or cleft palate, appears to hinge ... offer several potential drug targets. The study, published online ...
... Professor of Public Health and Director of Health Promotion ... evidence that supports relationships seen in adolescents between insulin ... fat and identifies additional potential early markers of insulin ... including fat in muscle cells, blood pressure, physical activity, ...
... HealthDay Reporter , FRIDAY, July 9 (HealthDay News) -- One ... of Avandia, new doubts surfaced Friday on a key trial ... A medical reviewer for the U.S. Food and Drug ... that drugmaker GlaxoSmithKline,s "mishandling" of trial results may have ...
... the 52nd meeting of the American Association of Physicists ... 22, 2010 in Philadelphia, PA, thousands of scientists and ... developments in medical imaging and radiation therapy, examine new ... ethical and regulatory issues that face the field today. ...
... Researchers at Brown University have found that the length of ... doubled during the last 10 years. The study, which will ... the American Geriatrics Society , evaluated hospice use in U.S. ... treatment time has increased from 46 to 93 days. The ...
... HCG True Diet offers ... ... photos and revamped the before and after section of the website. The pictures can be ... taken of a patient before they start the HCG True Diet and after they finish the ...
Cached Medicine News:Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 2Health News:Study implicates new epigenetic player in mental retardation and facial birth defects 3Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 2Health News:LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 2Health News:FDA Reviewer Questions Results of Key Avandia Trial 3Health News:FDA Reviewer Questions Results of Key Avandia Trial 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 2Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 3Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 4Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 5Health News:Preliminary highlights of the AAPM 52nd Annual Meeting, Philadelphia, Pa., July 18-22, 2010 6Health News:Study: Medicare policy may account for growing length of hospice stays in nursing homes 2Health News:See New HCG Diet Before and After Photos 2
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
VACUETTE PaediatricMulti-Sample Needle...
... Blood Collection Needles are preominantly used for ... single-use. The colour of the needle protective ... needle gauges. For example, yellow symbolises the ... 21 G (0.80 mm) and black 22 ...
This is adapted to microplate or card....
Medicine Products: